Oak Hill Bio Named Joerg Hipp as Science Chief
The Cambridge-based biotech company appointed a new executive to oversee clinical development of its drug pipeline.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you trust that pharmaceutical companies prioritize the development of treatments for rare diseases?
Oak Hill Bio has appointed Joerg Hipp as its new Chief Translational Science Officer. Hipp joins the Cambridge-based firm to lead the clinical development of rugonersen, a drug currently in a Phase 3 trial for Angelman syndrome.
Why it matters
Hipp brings extensive experience in biomarker research and neurodevelopmental medicine to the pivotal final stage of drug testing. His recruitment is aimed at accelerating the company's efforts to address the neurological pathology of Angelman syndrome.
Joerg Hipp brings 15 years of experience in neuroscience to the role, having authored approximately 70 peer-reviewed articles, including 10 focused specifically on Angelman syndrome.
The players
Joerg Hipp
He is the newly appointed Chief Translational Science Officer at Oak Hill Bio who holds a M.S. in Physics and a Dr. sc. nat. in Neuroscience.
Oak Hill Bio
This Cambridge-based biotechnology company focuses on developing targeted therapies for rare genetic diseases.
Roche
This is a multinational healthcare company where Hipp previously worked as a leader in biomarker and experimental medicine.
The details
Hipp previously served as a biomarker and experimental medicine leader at Roche, where he helped guide the initial clinical development of rugonersen. His work utilizes electroencephalogram technology as a biomarker to monitor the success of UBE3A restoration in patients.
Timeline
Oak Hill Bio was formed as a subsidiary in 2024.
Phase 1 TANGELO trial results were published in 2025.
Joerg Hipp was appointed Chief Translational Science Officer on October 6, 2026.
The Tech Race
This appointment follows the TANGELO Phase 1 trial for rugonersen, signaling a transition from early-stage research to pivotal Phase 3 development. It reflects a broader industry move toward hiring specialized neuroscientists to navigate complex regulatory and clinical endpoints for rare disease therapies.
The clinical progress of this drug could provide the first targeted therapeutic option for patients living with Angelman syndrome. Success in the current Phase 3 trials would significantly change the treatment landscape for those currently managing the condition's neurological symptoms.
The takeaway
The addition of a specialist like Hipp underscores the increasing reliance on complex biomarker data in modern drug development. Patients and their families should continue to monitor clinical trial registry updates for information on potential therapeutic access.
Further reading
For more information on industry developments, visit the Biotech section.
Live Poll
Do you trust that pharmaceutical companies prioritize the development of treatments for rare diseases?
